I have reviewed the archives related to clinical trial residual balances
and would like to know if any institutions have changed their policies
or implemented policies in light of some recent discussion of compliance
and tax issues with residual balances.

We are trying to implement stricter guidelines with the allowance and
use of residual balances and we are looking at the fair market value of
services vs. the reimbursement from the sponsor.  I have also noted new
language in many sponsor contracts specifically stating that we the
institution acknowledge and agree that the reimbursement for services is
at fair market value which was negotiated at arms length etc.

Does anyone currently perform an analysis of residual balances to
determine what the UBIT would be if any?  Does anyone currently report
the UBIT on their 990T?

Thanks

Kim Babbie

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================